P700: TREATMENT-FREE REMISSION (TFR) AFTER DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND DEEP MOLECULAR RESPONSE (DMR): FINAL 5-YEAR RESULTS OF DASFREE

• N. P. Shah,
• V. García-Gutiérrez,
• A. Jiménez-Velasco,
• S. Saussele,
• D. Rea,
• F.-X. Mahon,
• M. Y. Levy,
• M. T. Gómez-Casares,
• M. J. Mauro,
• O. Sy,
• P. Martin-Regueira,
• J. H. Lipton

Affiliations

N. P. Shah

1 UCSF School of Medicine, San Francisco, United States of America

V. García-Gutiérrez

2 Servicio Hematología y Hemoterapia, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid

A. Jiménez-Velasco

3 Hospital Universitario Carlos Haya, Malaga, Spain

S. Saussele

4 Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany

D. Rea

5 Hôpital Saint-Louis, Paris

F.-X. Mahon

6 Institut Bergonié Cancer Center, Université Bordeaux, Bordeaux, France

M. Y. Levy

7 Baylor Charles A. Sammons Cancer Center, Dallas, United States of America

M. T. Gómez-Casares

8 Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

M. J. Mauro

9 Memorial Sloan Kettering Cancer Center, New York

O. Sy

10 Bristol Myers Squibb, Princeton, United States of America

P. Martin-Regueira

10 Bristol Myers Squibb, Princeton, United States of America

J. H. Lipton

11 Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada